Analysts Offer Predictions for GSK's Q1 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK - Free Report) - Equities research analysts at Zacks Research lowered their Q1 2027 earnings per share estimates for shares of GSK in a report released on Monday, April 21st. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $1.07 per share for the quarter, down from their previous estimate of $1.11. The consensus estimate for GSK's current full-year earnings is $4.14 per share.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

GSK has been the topic of a number of other research reports. StockNews.com cut shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, April 16th. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target on the stock. Eight analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Stock Performance

Shares of GSK stock opened at $36.60 on Wednesday. The company has a market capitalization of $75.51 billion, a P/E ratio of 23.02, a P/E/G ratio of 1.12 and a beta of 0.56. GSK has a 12-month low of $31.72 and a 12-month high of $45.93. The business's 50 day moving average is $37.44 and its two-hundred day moving average is $36.06. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were given a dividend of $0.3932 per share. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.30%. GSK's dividend payout ratio (DPR) is presently 100.63%.

Institutional Trading of GSK

Several large investors have recently added to or reduced their stakes in the stock. Dorsey & Whitney Trust CO LLC grew its holdings in shares of GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 278 shares during the period. First PREMIER Bank increased its holdings in shares of GSK by 6.5% during the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock worth $181,000 after buying an additional 286 shares during the last quarter. Northwest Bank & Trust Co raised its position in shares of GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock valued at $765,000 after buying an additional 289 shares during the period. GC Wealth Management RIA LLC lifted its holdings in GSK by 2.6% in the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after acquiring an additional 353 shares during the last quarter. Finally, Rhumbline Advisers grew its position in GSK by 2.1% in the first quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company's stock worth $713,000 after acquiring an additional 386 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.